Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

Changhai Hospital60 enrolled

Overview

Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven colorectal cancer with liver metastasis * Aged between 18 and 70 years * Written informed and signed consent * Accessible to surgery sample of metastasis and primary tumor Exclusion Criteria: * Less than 18 years and older than 70 years * Not able to give informed consent * Not accessible to surgery sample

Locations (1)

Department of Colorectal Surgery in Changhai Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

The consistency of drug sensitivity

To test the consistency of drug sensitivity of primary tumor and its matched liver metastasis

Time frame: 3 years

Secondary Outcomes

The establishment of PDO

To test the rate of PDO derived from primary and matched metastatic colorectal cancer .

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.